Table 2 |
||||
| Frequencies of ADIPOQ genotypes in patients and controls | ||||
| Gene | CT | MHD | Controls | |
| (n = 32) | (n = 46) | (n = 70) | ||
|
+276 G>T Alleles |
G | 54(84.38%) | 73(79.35%) | 125(89.29%) |
| T | 10(15.62%) | 19(20.65%) b* | 15(10.71%) | |
| Genotypes | GG | 24(75.00%) | 32(69.56%) | 55(78.57%) |
| GT | 6(18.75%) | 9(19.57%) | 15(21.43%) | |
| TT | 2(6.25%) a* | 5(10.87%) b* | 0(0%) | |
|
+45 T>G Alleles |
T | 64(100%) | 92(100%) | 140(100%) |
| G | 0(0%) | 0(0%) | 0(0%) | |
| Genotypes | TT | 32(100%) | 46(100%) | 70(100%) |
| TG | 0(0%) | 0(0%) | 0(0%) | |
| GG | 0(0%) | 0(0%) | 0(0%) | |
Data was evaluated by the gene counting method. Values were presented as percentage. CT conservative treatment, MHD maintenance hemodialysis. aP < 0.05 vs. control and CT, bP < 0.05 vs. control and MHD.
Elshamaa et al. BMC Research Notes 2012 5:174 doi:10.1186/1756-0500-5-174
